Contact Information
37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG
Mizuho Initiates Coverage of Vigil Neuroscience (VIGL) with Buy Recommendation
On March 31, 2023, Mizuho initiated coverage of Vigil Neuroscience with a Buy recommendation. Analyst Price Forecast Suggests 109.31% Upside As of March 30, 2023,
Canaccord Genuity Initiates Coverage of Driven Brands Holdings (DRVN) with Buy Recommendation
On March 30, 2023, Canaccord Genuity initiated coverage of Driven Brands Holdings with a Buy recommendation. Analyst Price Forecast Suggests 32.33% Upside As of March
Canaccord Genuity Initiates Coverage of Lifetime Brands (LCUT) with Buy Recommendation
On March 30, 2023, Canaccord Genuity initiated coverage of Lifetime Brands with a Buy recommendation. Analyst Price Forecast Suggests 111.78% Upside As of March 30,
Stifel Initiates Coverage of Immunovant (IMVT) with Buy Recommendation
On March 30, 2023, Stifel initiated coverage of Immunovant with a Buy recommendation. Analyst Price Forecast Suggests 56.92% Upside As of March 30, 2023, the
Canaccord Genuity Initiates Coverage of Spectrum Brands Holdings (SPB) with Buy Recommendation
On March 30, 2023, Canaccord Genuity initiated coverage of Spectrum Brands Holdings with a Buy recommendation. Analyst Price Forecast Suggests 27.12% Upside As of March
TD Cowen Initiates Coverage of Waste Management (WM) with Outperform Recommendation
On March 30, 2023, TD Cowen initiated coverage of Waste Management with a Outperform recommendation. Analyst Price Forecast Suggests 9.32% Upside As of March 30,
Texas judge blocks Obamacare coverage mandate for PrEP, cancer screening By Reuters
© Reuters. FILE PHOTO: A sign on an insurance store advertises Obamacare in San Ysidro, San Diego, California, U.S., October 26, 2017. REUTERS/Mike Blake By
HC Wainwright & Co. Initiates Coverage of Legend Biotech (LEGN) with Buy Recommendation
On March 29, 2023, HC Wainwright & Co. initiated coverage of Legend Biotech with a Buy recommendation. Analyst Price Forecast Suggests 51.50% Upside As of
UBS Initiates Coverage of Edwards Lifesciences (EW) with Neutral Recommendation
On March 29, 2023, UBS initiated coverage of Edwards Lifesciences with a Neutral recommendation. Analyst Price Forecast Suggests 9.47% Upside As of March 29, 2023,
UBS Initiates Coverage of DexCom (DXCM) with Buy Recommendation
On March 29, 2023, UBS initiated coverage of DexCom with a Buy recommendation. Analyst Price Forecast Suggests 18.96% Upside As of March 28, 2023, the